Eledon Pharmaceuticals, Inc. Common Stock (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN) is a biotechnology company focused on developing novel therapies for inflammatory and neurodegenerative diseases. The company's lead programs target conditions such as amyotrophic lateral sclerosis (ALS) and organ transplant rejection, utilizing its proprietary Elededril platform to modulate the immune system and improve patient outcomes.
Company News
Eledon Pharmaceuticals will present topline results from its Phase 2 BESTOW trial evaluating tegoprubart for kidney transplant rejection prevention at the American Society of Nephrology's Kidney Week 2025 in Houston, TX.
The article discusses four small-cap stocks that offer high risk and high reward potential as investors rotate their portfolios. The stocks are from the biotech and electric vehicle sectors, with analysts seeing significant upside but also inherent risks.
Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Tuesday, Eledon Pharmaceuticals Inc (NASDAQ:ELDN) announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with tegoprubart for the prevention of pancreatic islet cell transplant rejection in type 1 diabetes patients. The company also reported updated data from its...
Penny stocks to watch this week. The post Penny Stocks To Buy Now? 4 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.